Johnson & Johnson revealed that 21 abstracts highlighting both real‑world and clinical trial findings will be presented at the U.S. Psychiatric & Mental Health Congress (Psych Congress), scheduled for September 17‑21 in San Diego, California. These presentations will draw on the Company’s neuropsychiatry portfolio, showcasing new data related to major depressive disorder (MDD), tre... https://www.coherentmarketinsights.com/news/johnson-johnson-announced-to-show-its-new-neuropsychiatry-innovations-1529